July 9, 2015 – NEW YORK — Internationally recognized stem cell researcher, founder, and chief medical officer of Blue Horizon International (BHI) and Blue Horizon Stem Cells (BHSC), Brian Mehling, M.D., is scheduled to speak at two upcoming conferences in Europe. One in Paris, France and the other in Rome, Italy.
The ICTERM 2015: 17th International Conference on Tissue Engineering and Regenerative Medicine in Paris aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results about all aspects of Tissue Engineering and Regenerative Medicine. It also provides the premier interdisciplinary forum for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns, practical challenges encountered and the solutions adopted in the field of Tissue Engineering and Regenerative Medicine. The conference is taking place from July 20-21 in Paris, France.
Dr Mehling will be one of the conference’s featured chairs on Tuesday, July 21.
The 4th International Conference on Tissue Science & Regenerative Medicine, which is being be held during July 27-29, 2015 at Rome, Italy, will bring together world-class personalities working on stem cells, tissue engineering, and regenerative medicine to discuss materials-related strategies for disease remediation and tissue repair. Bone tissue engineering, soft tissues, tissue imaging, tissue implant, cartilage, and skin defects are a special focus along with applying basic science and engineering principles from diverse areas toward solving clinically relevant biomedical problems.
Dr. Mehling will present on Wednesday July 29, 2015.
“Stem cell treatments are, without a doubt, the future of medicine and we believe their role in treatments will become the preferred substitutes for many surgical, pharmacological, and rehabilitative medical services,” Dr. Mehling stated. “It is important that doctors and medical professionals are educated on what direction the world will take in regard to stem cell research and therapies. The possibilities in stem cell research and regenerative medicine are endless. It is crucial for physicians to be aware of the therapies available for patients with different chronic conditions, disorders, and acute diseases.”
Blue Horizon Stem Cells is currently offering adipose stem cell derived treatment for joint diseases at Malacky Hospital in Slovakia and is planning to open a facility in Berlin, Germany soon. “We have treated more than 20 patients so far, all with outstanding results. Stem cells are a great option when the patient is not a good candidate for traditional forms of treatment, such as invasive surgery or other treatment modalities,”